366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of {PI3} kinase

A. Jimeno; R.S. Herbst; G.S. Falchook; W.A. Messersmith; D.R. Camidge; S.R. Peterson; D.F. Hausman; R. Kurzrock; S.G. Eckhardt; D.S. Hong

首页> 外文期刊>European Journal of Cancer Supplements >366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of {PI3} kinase

【24h】

366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of {PI3} kinase

机译：366对P {-PI3 }激酶的不可逆，泛亚型抑制剂PX-866进行连续给药的1期研究

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2010年第7期|共页
作者
A. Jimeno; R.S. Herbst; G.S. Falchook; W.A. Messersmith; D.R. Camidge; S.R. Peterson; D.F. Hausman; R. Kurzrock; S.G. Eckhardt; D.S. Hong;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
入库时间 2022-08-18 18:38:40

相似文献

外文文献
中文文献
专利

1. 366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of {PI3} kinase [J] . A. Jimeno, R.S. Herbst, G.S. Falchook, European Journal of Cancer Supplements . 2010,第7期

机译：366对P {-PI3 }激酶的不可逆，泛亚型抑制剂PX-866进行连续给药的1期研究
2. A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma [J] . Bowles Daniel W., Kochenderfer Mark, Cohn Allen, Clinical colorectal cancer . 2016,第4期

机译：转移性结直肠癌患者中西妥昔单抗的II期随机试验，有或没有PX-866，一种不可逆的口服磷脂酰肌醇3-激酶抑制剂。
3. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer [J] . Jimeno A., Shirai K., Choi M., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第3期

机译：西妥昔单抗有或无PX-866（一种不可逆的口服磷脂酰肌醇3激酶抑制剂）治疗复发或转移性头颈部鳞状细胞癌患者的II期随机试验
4. CNX-774, an Irreversible, Selective and Orally Bioavailable Inhibitor of Bruton's Tyrosine Kinase: In Vitro ADME, Selectivity, and Pharmacokinetic Properties [C] . Prasoon Chaturvedi, Matthew Labenski, Erica Evans, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：CNX-774，Bruton的酪氨酸激酶的不可逆转，选择性和口服生物可利用的抑制剂：体外Adme，选择性和药代动力学性能
5. Development of cell-active irreversible inhibitors of the human centrosomal kinase Nek2. [D] . Henise, Jeffrey C. 2011

机译：人中心体激酶Nek2的细胞活性不可逆抑制剂的开发。
6. A randomized phase 2 trial of docetaxel with or without PX-866 an irreversible oral phosphatidylinositol 3-kinase inhibitor in patients with relapsed or metastatic head and neck squamous cell cancer [O] . Antonio Jimeno, Julie E. Bauman, Charles Weissman, -1

机译：多西他赛有或没有PX-866（一种不可逆的口服磷脂酰肌醇3-激酶抑制剂）治疗复发或转移性头颈部鳞状细胞癌患者的2期随机试验
7. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer [O] . Antonio Jimeno, Julie E. Bauman, Charles Weissman, 2015

机译：多西紫杉醇的随机，相2试验或没有PX-866，一种不可逆口服磷脂酰肌醇3-激酶抑制剂，患者复发或转移头和颈部鳞状细胞癌

366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of {PI3} kinase

著录项

相似文献

相关主题

期刊订阅